论文部分内容阅读
目的:观察丹红注射液联合泮托拉唑治疗呼吸衰竭急性加重期的临床疗效。方法:选取100例呼吸衰竭急性加重期的患者,对照组进行常规治疗,试验组在常规治疗基础上加用丹红注射液联合泮托拉唑治疗,治疗2周后比较2组的治疗效果。结果:2组治疗前血浆黏度、血浆乳酸、动脉血氧分压(PaO2)、动脉血氧饱和度(SaO2)、动脉血二氧化碳分压(PaCO2)等指标比较,差异均无显著性意义(P>0.05),具有可比性。2组治疗后血浆黏度和血浆乳酸及PaCO2值均有所降低,试验组降低程度明显优于对照组(P<0.05);2组治疗后PaO2、SaO2值均有所升高,试验组升高程度明显优于对照组(P<0.05)。结论:丹红注射液联合泮托拉唑治疗呼吸衰竭急性加重期的临床疗效值得肯定,建议在临床上推广使用。
Objective: To observe the clinical efficacy of Danhong injection combined with pantoprazole in the treatment of respiratory failure in acute exacerbation. Methods: A total of 100 patients with acute exacerbation of respiratory failure were enrolled in this study. Patients in the control group were treated routinely. The experimental group was given Danhong injection combined with pantoprazole on the basis of routine treatment. The therapeutic effect was compared between the two groups after 2 weeks of treatment. Results: The plasma viscosity, plasma lactic acid, PaO2, SaO2 and PaCO2 of two groups before treatment had no significant difference (P > 0.05), comparable. After treatment, plasma viscosity, plasma lactic acid and PaCO2 decreased in both groups, and the degree of decrease in the experimental group was significantly better than that in the control group (P <0.05). PaO2 and SaO2 values were increased in both groups after treatment, The degree was significantly better than the control group (P <0.05). Conclusion: Danhong injection combined with pantoprazole in the treatment of respiratory failure acute exacerbation of clinical efficacy is worthy of approval, it is recommended for clinical use.